Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SGN-30's growth arrest and synergistic effects with chemotherapeutics for HD

Oct. 11, 2005

Viventia Biotech reports update on VB4-845 for bladder cancer

Oct. 11, 2005

Orphan drug status for ZymoGenetics' IL-21 for melanoma

Oct. 7, 2005

Canadian clearance for phase II trial of Proxinium

Oct. 7, 2005

Discontinuation of phase III Canvaxin study in stage III melanoma

Oct. 5, 2005

Wyeth launches Mylotarg in Japan for acute myelocytic leukemia

Oct. 4, 2005

Canvaxin improves survival of patients with high-risk melanoma

Sep. 29, 2005

Low dose oral interferon alpha studied for bone marrow proliferative disorders

Sep. 29, 2005

Enrollment discontinued in Avastin phase II study in ovarian cancer

Sep. 28, 2005

NeuTec Pharma to evaluate Mycograb for breast cancer

Sep. 22, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...